Maxcyte (MXCT) Depreciation & Amortization (CF) (2020 - 2026)

Maxcyte (MXCT) has reported Depreciation & Amortization (CF) for 7 consecutive years, with $978000.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Depreciation & Amortization (CF) fell 11.09% year-over-year to $978000.0 in Q2 2026; TTM through Jun 2026 was $4.2 million, a 3.47% decrease from a year earlier, with the FY2025 full-year figure at $4.3 million, up 0.58% from the prior year.
• Depreciation & Amortization (CF) was $978000.0 for Q2 2026 at Maxcyte, down from $1.0 million in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $1.1 million in Q1 2024 and troughed at $487400.0 in Q1 2022.
• A 5-year average of $974933.3 and a median of $1.1 million in 2024 frame the typical range for Depreciation & Amortization (CF).
• Across the five-year window, Depreciation & Amortization (CF) surged 120.82% in 2022 and declined 11.09% in 2026, its largest moves.
• Over 5 years, Depreciation & Amortization (CF) stood at $919700.0 in 2022, then increased by 19.82% to $1.1 million in 2023, then retreated by 4.08% to $1.1 million in 2024, then climbed by 1.42% to $1.1 million in 2025, then retreated by 8.77% to $978000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $978000.0 (Q2 2026), $1.0 million (Q1 2026), and $1.1 million (Q4 2025), per Business Quant data.